Taipei Medical University (TMU) and Merck Sharp & Dohme (MSD) Taiwan have signed a Memorandum of Understanding to collaborate in six key directions aiming to advance healthcare in Taiwan.
This partnership, the very first large-scale alliance between a global pharmaceutical company and a medical university in Taiwan, will inject international resources into the country’s healthcare innovation ecosystem and enhance its biotechnology and pharmaceutical competitiveness.
TMU Office of Business Development will form the “MSD Innovative Strategic Partnership” with industry experts at MSD to provide business mentorship, clinical validation, and collaboration with startups.
TMU Office of Human Research will work with clinical trial experts at MSD to enhance clinical trial capabilities across TMU’s affiliated hospitals to improve efficiency.
TMU Office of Academic Affairs will work with human resource experts at MSD to create new industry-oriented practical curricula for TMU students with aims to combine academic knowledge with workplace skills and to increase international visibility for Taiwanese young talents.
TMU Office of Data Science will work with MSD clinico-marketing experts to develop real-world evidence (RWE) projects. TMU Center for Management and Development will establish an “Expedited New Drug Pathway” to streamline access to innovative therapeutics, especially first-in-class innovative pharmaceuticals which had been tested in clinical trials within TMU’s 3,000-bed healthcare systems.
TMU Taipei Cancer Center will coordinate the Enhanced Recovery After Surgery (ERAS) programs and optimize patient journeys to ensure early diagnosis and early treatment.
